Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis
Malignant tumors have become the main cause of harm to human life and health. Development for new antitumor drugs and the exploration to drug carriers are becoming the concerned focus. In this study, we exploited our experiments to explore the effect of NCTD-NLC on liver cancer cells: the HepG2 cell...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/3851604 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306974441701376 |
|---|---|
| author | Zijun Yan Kun Yang Xiang Tang Yunfeng Bi Yuzhen Ding Mengyue Deng Die Xia Yunqi Zhao Tong Chen |
| author_facet | Zijun Yan Kun Yang Xiang Tang Yunfeng Bi Yuzhen Ding Mengyue Deng Die Xia Yunqi Zhao Tong Chen |
| author_sort | Zijun Yan |
| collection | DOAJ |
| description | Malignant tumors have become the main cause of harm to human life and health. Development for new antitumor drugs and the exploration to drug carriers are becoming the concerned focus. In this study, we exploited our experiments to explore the effect of NCTD-NLC on liver cancer cells: the HepG2 cells cultured in vitro were given with NCTD-NLC administration; then, the estimation on cellular proliferation and apoptosis was accomplished through MTT and flow cytometry. Six hours after the administration, we performed the High Performance Liquid Chromatography (HPLC) detection to estimate the NCTD content in the heart, liver, spleen, lung, kidney and plasma of rats. Then, our outcomes showed that NCTD-NLC had a notable inhibitory effect on HepG2 cells, leading to a gradually decreased cellular viability. Cell viability was negatively correlated with NCTD-NLC concentration. Along with the concentration increasing, significantly increasing cellular apoptosis and gradually decreasing cellular viability were observed. The apoptosis rate was positively correlated with the concentration of NCTD-NLC. On the basis of the data we obtained, we found that the group with NCTD-NLC tail vein injection had an obvious advantage in drug delivery when compared with other groups. Through the tumorigenesis test to nude mice, we found that the tumor inhibition rate of the NCTD-NLC tail vein injection group had a 27.48% elevation in contrast to the NCTD gavage group, and it was also the group with the best tumor inhibition efficiency. In conclusion, the NCTD-NLC prepared in this study had a mighty inhibitory effect towards HepG2 cellular viability and an accelerating work on apoptosis. Tail vein injection of NCTD-NLC has the best drug delivery effect. |
| format | Article |
| id | doaj-art-1dc1bbd5486c43029ded1e39c43bf7ca |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-1dc1bbd5486c43029ded1e39c43bf7ca2025-08-20T03:54:56ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/3851604Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the ApoptosisZijun Yan0Kun Yang1Xiang Tang2Yunfeng Bi3Yuzhen Ding4Mengyue Deng5Die Xia6Yunqi Zhao7Tong Chen8School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural ProductsDepartment of PharmacySchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural ProductsSchool of PharmacySchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural ProductsSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural ProductsSchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural ProductsCollege of Science and TechnologySchool of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural ProductsMalignant tumors have become the main cause of harm to human life and health. Development for new antitumor drugs and the exploration to drug carriers are becoming the concerned focus. In this study, we exploited our experiments to explore the effect of NCTD-NLC on liver cancer cells: the HepG2 cells cultured in vitro were given with NCTD-NLC administration; then, the estimation on cellular proliferation and apoptosis was accomplished through MTT and flow cytometry. Six hours after the administration, we performed the High Performance Liquid Chromatography (HPLC) detection to estimate the NCTD content in the heart, liver, spleen, lung, kidney and plasma of rats. Then, our outcomes showed that NCTD-NLC had a notable inhibitory effect on HepG2 cells, leading to a gradually decreased cellular viability. Cell viability was negatively correlated with NCTD-NLC concentration. Along with the concentration increasing, significantly increasing cellular apoptosis and gradually decreasing cellular viability were observed. The apoptosis rate was positively correlated with the concentration of NCTD-NLC. On the basis of the data we obtained, we found that the group with NCTD-NLC tail vein injection had an obvious advantage in drug delivery when compared with other groups. Through the tumorigenesis test to nude mice, we found that the tumor inhibition rate of the NCTD-NLC tail vein injection group had a 27.48% elevation in contrast to the NCTD gavage group, and it was also the group with the best tumor inhibition efficiency. In conclusion, the NCTD-NLC prepared in this study had a mighty inhibitory effect towards HepG2 cellular viability and an accelerating work on apoptosis. Tail vein injection of NCTD-NLC has the best drug delivery effect.http://dx.doi.org/10.1155/2022/3851604 |
| spellingShingle | Zijun Yan Kun Yang Xiang Tang Yunfeng Bi Yuzhen Ding Mengyue Deng Die Xia Yunqi Zhao Tong Chen Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis Journal of Immunology Research |
| title | Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis |
| title_full | Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis |
| title_fullStr | Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis |
| title_full_unstemmed | Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis |
| title_short | Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis |
| title_sort | norcantharidin nanostructured lipid carrier nctd nlc suppresses the viability of human hepatocellular carcinoma hepg2 cells and accelerates the apoptosis |
| url | http://dx.doi.org/10.1155/2022/3851604 |
| work_keys_str_mv | AT zijunyan norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis AT kunyang norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis AT xiangtang norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis AT yunfengbi norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis AT yuzhending norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis AT mengyuedeng norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis AT diexia norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis AT yunqizhao norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis AT tongchen norcantharidinnanostructuredlipidcarriernctdnlcsuppressestheviabilityofhumanhepatocellularcarcinomahepg2cellsandacceleratestheapoptosis |